← All trials
NCT03877471
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 3, 2019
- Primary completion
- Jul 1, 2020
- Completion date
- Dec 31, 2021
- First posted
- Mar 15, 2019
- Last posted
- Aug 5, 2021
- Enrollment
- 28
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Zhengzhou UniversityCollaborator
- National Natural Science Foundation of ChinaCollaborator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Chinese Academy of Medical SciencesReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.